ALT - Altimmune, Inc.

QQQ $ 620.90 $ 0.00 (0 %)

DIA $ 473.88 $ 0.00 (0 %)

SPY $ 679.98 $ 0.00 (0 %)

TLT $ 89.39 $ 0.00 (0 %)

GLD $ 381.10 $ 0.00 (0 %)

Previous Close

$ 4.26

Open

$ 4.24

Bid

$ 4.20 x 150

Ask

$ 4.32 x 100

Day's Range

-- - --

52 Week Range

$ 2.90 - $ 11.16

Volume

6,038,077

Average Volume

Market Cap

444.12M

Beta (5Y Monthly)

$ 1.11

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-06-2025	09-30-2025	10-Q
2	08-12-2025	06-30-2025	10-Q
3	05-13-2025	03-31-2025	10-Q
4	02-27-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	05-09-2024	03-31-2024	10-Q
8	03-27-2024	12-31-2023	10-K
9	11-07-2023	09-30-2023	10-Q
10	08-10-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	02-28-2023	12-31-2022	10-K
13	11-10-2022	09-30-2022	10-Q
14	08-11-2022	06-30-2022	10-Q
15	05-12-2022	03-31-2022	10-Q
16	03-15-2022	12-31-2021	10-K
17	11-09-2021	09-30-2021	10-Q
18	08-10-2021	06-30-2021	10-Q
19	05-17-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-09-2020	09-30-2020	10-Q
22	08-11-2020	06-30-2020	10-Q
23	05-13-2020	03-31-2020	10-Q
24	03-27-2020	12-31-2019	10-K
25	11-13-2019	09-30-2019	10-Q
26	08-13-2019	06-30-2019	10-Q
27	05-14-2019	03-31-2019	10-Q
28	04-01-2019	12-31-2018	10-K
29	11-13-2018	09-30-2018	10-Q
30	08-14-2018	06-30-2018	10-Q
31	05-15-2018	03-31-2018	10-Q
32	04-02-2018	12-31-2017	10-K
33	11-09-2017	09-30-2017	10-Q
34	08-14-2017	06-30-2017	10-Q
35	05-03-2017	03-31-2017	10-Q
36	03-14-2017	12-31-2016	10-K
37	11-04-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-09-2016	03-31-2016	10-Q
40	03-11-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Citizens Maintains Market Outperform on Al...
11/07/2025 13:37:56

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target fro...

Altimmune Data From AI-Based Analysis Of B...
11/07/2025 13:14:39

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for ...

Altimmune Q3 EPS $(0.21) Beats $(0.27) Est...
11/06/2025 12:07:45

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 2...

Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

Altimmune Completes Patient Enrollment In ...
11/03/2025 12:37:29

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic opti...

HC Wainwright & Co. Reiterates Buy on Alti...
10/20/2025 11:59:45

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price tar...

Altimmune To Present 24-Week Data From Pha...
10/20/2025 11:36:43

Oral presentation to highlight 24-week efficacy and safety dataPoster to feature results of AI-based analyses of liver fibrosis...

Altimmune Stock: A Deep Dive Into Analyst ...
10/10/2025 12:02:09

HC Wainwright & Co. Reiterates Buy on Alti...
10/10/2025 11:04:27

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price tar...

10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

radian-group-intel-nanobiotix-crowdstrike-and-other-big-stocks-moving-higher-on-thursday

Radian Group, Intel, Nanobiotix, CrowdStri...
09/18/2025 14:19:12

Altimmune Announces Pemvidutide As The Onl...
08/19/2025 11:33:43

Pemvidutide is the only drug currently granted Fast Track Designation in AUDRECLAIM, a Phase 2 trial of pemvidutide in AUD, is ...

What 5 Analyst Ratings Have To Say About A...
08/13/2025 21:01:18

these-analysts-slash-their-forecasts-on-altimmune-following-q2-results

These Analysts Slash Their Forecasts On Al...
08/13/2025 18:57:23

HC Wainwright & Co. Reiterates Buy on Alti...
08/13/2025 17:49:53

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.

UBS Maintains Buy on Altimmune, Lowers Pri...
08/13/2025 15:51:40

UBS analyst Eliana Merle maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $26 to $24.

B. Riley Securities Maintains Buy on Altim...
08/13/2025 12:34:39

B. Riley Securities analyst Mayank Mamtani maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $20 ...

Altimmune Q2 FY2025 Earnings Call Transcript
08/12/2025 14:18:39

Altimmune Q2 FY2025 earnings call transcript

Altimmune Q2 EPS $(0.27) Beats $(0.32) Est...
08/12/2025 11:03:11

Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28